Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Cannabis Administration for Dementia Allowed in Nursing Homes? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As medical cannabis becomes more visible in the UK, families and care providers are increasingly asking whether it can be used in nursing homes for people living with dementia. The short answer is only under strict legal and clinical conditions, and in most cases, routine administration is not yet allowed. 

Can medical cannabis be accessed legally for women’s health?

Legal Framework and Regulation 

Cannabis-based medicinal products (CBPMs) are legal in the UK only when prescribed by a specialist doctor registered with the General Medical Council. They are classed as Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, meaning all handling and administration must follow controlled drugs legislation (NHS England, 2023). 

In care or nursing homes, these medicines can only be used if prescribed, stored, and documented correctly. The Care Quality Commission (CQC) requires homes to maintain a full controlled drugs register, ensure secure storage, and record every administration step, including batch number and expiry date (CQC Controlled Drugs Annual Report 2024, 2025). 

Clinical Guidance and Ethics 

According to NICE dementia guidance (NG97) and NICE cannabis-based products guidance (NG144), cannabis is not recommended for dementia symptoms such as agitation or confusion outside formal research. 

If a resident is prescribed a CBPM, care homes must follow NICE SC1 rules on managing medicines including staff competency, consent assessment under the Mental Capacity Act 2005, and precise MAR (Medication Administration Record) documentation (NICE SC1). The Alzheimer’s Society warns that homes should not administer cannabis products without written medical direction, as doing so breaches CQC and Home Office regulations. Covert administration, giving medication without consent, requires legal authorisation and multidisciplinary approval. 

Research And Real-World Evidence 

The STAND trial at King’s College London is currently evaluating a THC: CBD spray (Sativex) for agitation in dementia, but this research is taking place in memory clinics, not nursing homes (Alzheimer’s Research UK, 2025). No national care-home pilot programmes are yet approved. 

Clinical Bottom Line 

  • CBPMs are legal only with a specialist prescription and controlled-drug compliance. 
  • Routine use in nursing homes is not authorised under current law. 
  • Staff must be trained, registered, and follow Mental Capacity Act best-interest procedures. 
  • Any administration requires CQC oversight and formal MAR recording. 

Educational Context: AlleviMed 

AlleviMed provides educational information about the UK’s regulated medical cannabis framework. It helps explain prescribing, safety, and monitoring procedures for clinicians and carers, supporting informed decision-making within legal boundaries. 

Takeaway 

Cannabis administration for dementia is not permitted as routine practice in UK nursing homes. It may only occur under specialist prescription, with full documentation, trained staff, and compliance with CQC and NHS England controlled-drug regulations. For now, safety, legality, and ethical governance remain the foundation of any potential use. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories